Climate and human rights campaigners filed a complaint against the European Commission on Friday, accusing the EU executive ...

The European Union's increasingly stringent environmental regulations are saddling global chemical companies with more than ...

Leveraging Trump’s impending tariffs, pharma companies have called on Europe again to change regulation, threatening a US ...

Pharma companies including Pfizer and MSD warn EU their €100bn investment plans could shift to the US over tariffs ...

Europe's pharma sector now trails the US, it went on to say, "on every investor metric from availability of capital, ...

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

Pharma companies are leveraging the United States’ threat of tariffs on drug imports to push for policy changes in the EU. | ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sarepta will start testing a new gene therapy for limb-girdle muscular dystrophy.

President Trump unveiled a wide-ranging executive order that aims to lower drug prices, boost transparency into fees charged ...

Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a ...

The United States is the biggest market by sales for big pharma companies, and Europe and the United States have ...